Latest Breaking News On - Aryogen biopharma - Page 3 : comparemela.com

Global TNF Alpha Inhibitors Markets 2020-2030: Remicade (infliximab), Enbrel (etanercept), Humira (adalimumab), Cimzia (certolizumab pegol), & Simponi (golimumab)

Global TNF Alpha Inhibitors Markets 2020-2030: Remicade (infliximab), Enbrel (etanercept), Humira (adalimumab), Cimzia (certolizumab pegol), & Simponi (golimumab)
prnewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from prnewswire.com Daily Mail and Mail on Sunday newspapers.

United statesAryogen biopharmaHanall biopharmaZydus cadilaSamsung bioepisLaura woodCelgene corporationReliance life sciencesPfizer incAbbvie incNovartis internationalJohnson services incOffice hours callDrug administrationMomenta pharmaceuticalsSegmentation by route of administration

Global Filgrastim Biosimilars Market Report 2020: COVID-19 Impacts, Growth and Changes

Share this article Share this article ResearchAndMarkets.com s offering. Major players in the filgrastim biosimilars market are Cadila Pharmaceuticals, Dr. Reddy s Laboratories, Intas Biopharmaceuticals, Sandoz, Amgen Inc., Dr. Reddy s Laboratories Ltd, Intas Pharmaceuticals, Emcure Pharmaceuticals Ltd., Biocon and Aryogen Biopharma. The global filgrastim biosimilars market is expected to decline from $511.15 million in 2019 to $445.04 million in 2020 at a compound annual growth rate (CAGR) of -12.93%. The decline is mainly due to the COVID-19 outbreak that has led to restrictive containment measures involving social distancing, remote working, and the closure of industries and other commercial activities resulting in operational challenges. The entire supply chain has been disrupted, impacting the market negatively. The market is then expected to recover and reach $751.96 billion in 2023 at a CAGR of 19.11%.

Adello biologicsKashiv biosciencesAryogen biopharmaKashiv pharmaLaura woodReliance life sciences pvtBiosimilar awareness initiativeBiosimilar medicines associationCustom researchRoche ltdAbbott laboratories incTeva pharmaceuticals industriesOffice hours callEmcure pharmaceuticals ltdDrug administrationClaris lifesciences

Filgrastim Biosimilars Global Market Report 2020-30: COVID-19 Growth and Change - Press Release

Filgrastim Biosimilars Global Market Report 2020-30: COVID-19 Growth and Change New York, Dec. 18, 2020 (GLOBE NEWSWIRE) Reportlinker.com announces the release of the report Filgrastim Biosimilars Global Market Report 2020-30: COVID-19 Growth and Change - https://www.reportlinker.com/p05998720/?utm source=GNW , Biocon and Aryogen Biopharma. The global filgrastim biosimilars market is expected to decline from $511.15 million in 2019 to $445.04 million in 2020 at a compound annual growth rate (CAGR) of -12.93%. The decline is mainly due to the COVID-19 outbreak that has led to restrictive containment measures involving social distancing, remote working, and the closure of industries and other commercial activities resulting in operational challenges. The entire supply chain has been disrupted, impacting the market negatively. The market is then expected to recover and reach $751.96 billion in 2023 at a CAGR of 19.11%.

New yorkUnited statesNew jerseyAdello biologicsKashiv biosciencesAryogen biopharmaKashiv pharmaEuropean medicines agencyBiosimilar awareness initiativeDrug administrationBiosimilar medicines associationBiosimilars global market reportFuji pharmaBiosimilar action planபுதியது யார்க்ஒன்றுபட்டது மாநிலங்களில்